Necrostatin 2 racemate (Nec-1s)

Catalog No.S8641 Batch:S864104

Print

Technical Data

Formula

C13H12ClN3O2
Molecular Weight 277.71 CAS No. 852391-15-2
Solubility (25°C)* In vitro DMSO 56 mg/mL (201.64 mM)
Ethanol 18 mg/mL (64.81 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Necrostatin 2 racemate (Nec-1s, 7-Cl-O-Nec1, Necrostatin-1 stable, Necrostatin 1S) is a stable variant of Necrostatin-1. This compound is a more specific RIPK1 inhibitor lacking the IDO-targeting effect, with >1000-fold more selective for RIPK1 than for any other kinase out of 485 human kinases.
Targets
RIPK1 [1]
In vitro

Necrostatin 2 racemate (Nec-1s) is a potent inhibitor of RIPK1 and cellular necroptosis while lacking IDO inhibitory activity.
In vivo

Necrostatin 2 racemate (Nec-1s) is effective in reducing brain injuries. It is a superior inhibitor suitable for use in vivo lacking a paradoxical sensitizing effect in TNF-induced lethality.

This compound possesses several advantageous pharmacokinetic and pharmacodynamic characteristics in comparison to Nec-1. Its safety profile is also superior to that of Nec-1 for reduced in vivo and in vitro toxicity.

Protocol (from reference)

Cell Assay:

[3]
  • Cell lines

    BMDMs

  • Concentrations

    50 µM

  • Incubation Time

    6 h

  • Method

    Cells were treated with indicated concentrations of Necrostatin 2 racemate (Nec-1s).
Animal Study:

[1]
  • Animal Models

    TNF-induced SIRS model (Female C57BL/6J WT mice)

  • Dosages

    0.6 mg/kg and 6 mg/kg

  • Administration

    i.v.

References

  • https://pubmed.ncbi.nlm.nih.gov/23190609/
  • https://pubmed.ncbi.nlm.nih.gov/30081531/
  • https://pubmed.ncbi.nlm.nih.gov/36198273/

Selleck's Necrostatin 2 racemate (Nec-1s) Has Been Cited by 76 Publications

Iron promotes both ferroptosis and necroptosis in the early stage of reperfusion in ischemic stroke [ Neural Regeneration Research, Not available, Not available] PubMed: 39286656
The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity [ Cell Reports, June 15, 2021, 109235] PubMed: 34133924
Nonstructural Protein NSs Activates Inflammasome and Pyroptosis through Interaction with NLRP3 in Human Microglial Cells Infected with Severe Fever with Thrombocytopenia Syndrome Bandavirus [ Journal of Virology, June 13, 2022, Not available]
RIPK1 Regulates Microglial Activation in Lipopolysaccharide-Induced Neuroinflammation and MPTP-Induced Parkinsons Disease Mouse Models [ Cells, January 26, 2023, 417] PubMed: 36766759
Ddb1 Is Essential for the Expansion of CD4+ Helper T Cells by Regulating Cell Cycle Progression and Cell Death [ Frontiers in Immunology, August 29, 2021, 724045] PubMed: 34526995
SIGLEC12 mediates plasma membrane rupture during necroptotic cell death [ Nature, 2025, 10.1038/s41586-025-09741-1] PubMed: 41225007
Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia [ Cell, 2025, S0092-8674(25)01233-4] PubMed: 41265435
Radiotherapy promotes cuproptosis and synergizes with cuproptosis inducers to overcome tumor radioresistance [ Cancer Cell, 2025, S1535-6108(25)00132-1] PubMed: 40215978
Simvastatin overcomes the pPCK1-pLDHA-SPRINGlac axis-mediated ferroptosis and chemo-immunotherapy resistance in AKT-hyperactivated intrahepatic cholangiocarcinoma [ Cancer Commun (Lond), 2025, 10.1002/cac2.70036] PubMed: 40443016
MLKL‒OPTN axis regulates herpesvirus-induced neurological sequelae [ Clin Transl Med, 2025, 15(6):e70353] PubMed: 40490945

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.